First Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, Japan
Received 10 May 2005; returned 25 July 2005; revised 21 September 2005; accepted 3 October 2005
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Methods: The conventional MICs were determined by the microbroth dilution method. Intracellular activities of drugs were evaluated by a cfu count. The minimal extracellular concentration inhibiting intracellular growth of bacteria (MIEC) was determined by a colorimetric cytopathic assay.
Results: MICs of pazuloxacin and tosufloxacin at which 90% (MIC90) of isolates are inhibited in 76 different Legionella spp. strains (38 ATCC strains and 38 clinical isolates) were 0.032 and 0.016 mg/L, whereas the MIC90s of levofloxacin, ciprofloxacin, garenoxacin, erythromycin, clarithromycin and azithromycin were 0.032, 0.032, 0.032, 2.0, 0.125 and 2.0 mg/L, respectively. Pazufloxacin and tosufloxacin at 4x MIC inhibited intracellular growth of Legionella pneumophila SG1 (80-045 strain), as did other quinolones, clarithromycin and azithromycin, whereas erythromycin at 4x MIC did not. MIECs of pazufloxacin, tosufloxacin, levofloxacin, ciprofloxacin and garenoxacin for the strain were 0.063, 0.004, 0.016, 0.032 and 0.008 mg/L respectively, which were superior to those of macrolides and azithromycin. Pazufloxacin showed potent activity against three additional clinical isolates of L. pneumophila SG1, one clinical isolate each of L. pneumophila SG3 and SG5, as well as Legionella micdadei, Legionella dumoffii and Legionella longbeachae SG1.
Conclusions: Pazufloxacin and tosufloxacin, as well as other quinolones, were more potent than macrolides and an azalide. Present data warrant further study on the efficacy of these drugs in the treatment of Legionella infections.
Keywords: intracellular activity , MIEC , MIC , Legionnaires' diseases , fluoroquinolones
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Pazufloxacin mesilate is a fluoroquinolone synthesized by Toyama Chemical Co. Ltd (Tokyo, Japan). This drug has good in vitro and in vivo activity against a broad range of bacteria, especially Gram-negative bacteria.9,10 Clinical trials showed its intravenous injection formula was effective in treating respiratory infections11 and the drug has been approved and is available in Japan. Tosufloxacin has good antimicrobial activity against respiratory pathogens and shows good clinical efficacy in respiratory infections.12 These drugs might be useful for treatment of Legionella infection as well.
In this study, the in vitro activity of pazufloxacin and tosufloxacin against Legionella spp. was evaluated using two methods: extracellular activity (MICs by the microdilution method) and intracellular activity (cfu counting method and colorimetric cytopathic assay13), and the activity was compared with other quinolones, macrolides and an azalide.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Bacterial strains used in the study included 38 ATCC reference strains of different Legionella spp. and serotypes (listed in Table 1) and 38 clinical isolates. The latter were the strains isolated from clinical specimens and collected in our laboratory, which included 29 strains of Legionella pneumophila SG1, four strains of L. pneumophila SG5, two strains of Legionella micdadei, and one strain of L. pneumophila SG3, Legionella dumoffii and Legionella longbeachae SG1. These strains were stocked in our laboratory and used for MIC determination. Clinical isolates of Legionella spp. were identified on the basis of their biochemical profile, direct fluorescent antibody test (m-Tech, Alpharetta, GA, USA) and a DNA hybridization technique using photobiotin-labelled bacterial DNA.14 The bacteria were cultured on buffered charcoal yeast extract supplemented with -ketoglutarate (BCYE-
; Difco Laboratories, Detroit, MI, USA) plates at 35°C for 23 days for use in each experiment.
|
The following antimicrobial agents were obtained as powders of known potency from their respective manufacturers: pazufloxacin, tosufloxacin and garenoxacin (Toyama Chemicals Ltd, Tokyo, Japan); ciprofloxacin (Bayer Yakuhin Ltd, Osaka, Japan); levofloxacin (Daiichi Pharmaceutical Co., Ltd, Tokyo, Japan); erythromycin base (Wako Pure Chemicals, Osaka, Japan); clarithromycin (Taishotoyama Pharmaceutical Co. Ltd, Tokyo, Japan); and azithromycin (Pfizer Pharmaceutical Ltd, Tokyo, Japan).
MIC determination
The MIC of each antimicrobial agent for Legionella was determined by the microdilution method15 using ACES-buffered yeast extract supplemented with -ketoglutarate (BYE-
) broth. Bacterial suspension (50 µL) was inoculated into BYE-
broth (50 µL) containing serial dilutions of the antibiotics in a 96-well microplate (inoculum size: 5 x 104 cfu/well). The MIC was defined as the minimum concentration of the drug that inhibited visible bacterial growth after culture at 35°C for 2 days. Staphylococcus aureus ATCC 25923 and Escherichia coli ATCC 25922 were used as control strains.
Intracellular antimicrobial activity testing
A murine macrophage J774.1 cell line (purchased from Riken Cell Bank, Tsukuba, Japan) was permissive for intracellular growth of Legionella and was used as the in vitro infection model for evaluating the intracellular activity of the antimicrobials.16,17 The macrophage cells were maintained in RPMI 1640 (Nipro, Osaka, Japan) supplemented with 10% fetal bovine serum in humidified air containing 5% CO2 at 37°C. For experiments, the cells were subcultured in RPMI 1640 supplemented with 5% fetal calf serum in a 96-well flat-bottom tissue culture plate (1 x 105 cells/well). The macrophages were then infected with Legionella (1 x 106 cfu/well). After culture for 12 h, the extracellular fluids and bacteria were aspirated, and the remaining cells were washed once. Antimicrobials were added to each well at the indicated concentrations, and the cells then incubated for 3 days. The number of viable Legionella in each well was determined by cfu counting as previously described.13
The activity of drugs against intracellular L. pneumophila was also evaluated using a previously described quantitative colorimetric assay system13,17 with minor modifications. The viability of macrophages was quantified using a rapid colorimetric assay employing the tetrazolium dye procedure. Treatment of Legionella-infected J774.1 cells with 2-fold dilutions of the drug allowed measurement of the doseresponse curve of each drug against the cytopathic effect of the bacteria.13,17
Statistical analysis
Distributions of MICs between different groups were analysed by ANOVA and Scheffe's test using software (Statview, SAS Institute Inc., NC, USA). A P-value <0.05 is considered as significant.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The MICs of various antimicrobials were evaluated for standard and clinical strains of Legionella. MIC50 and MIC90 of pazufloxacin for Legionella spp. bacteria were both 0.032 mg/L, which was identical to those of levofloxacin and ciprofloxacin, but lower than those of erythromycin, clarithromycin and azithromycin (Table 2). MICs of tosufloxacin were lower than those of other quinolones (Table 2). MICs of azithromycin for non-L. pneumophila were significantly higher than those for L. pneumophila SG1 and L. pneumophila SG2-14 (Table 3), while no difference was detected in MIC distributions of other drugs between L. pneumophila SG1, L. pneumophila SG2-14 and non-L. pneumophila.
|
|
The activity of drugs was evaluated using the J774.1 macrophage in vitro infection model (Figure 1). MICs for L. pneumophila SG1 (strain 80-045) of pazufloxacin, tosufloxacin, levofloxacin, ciprofloxacin, garenoxacin, erythromycin, clarithromycin and azithromycin were 0.032 (mg/L), 0.016, 0.032, 0.032, 0.016, 0.125, 0.063 and 0.125, respectively. This strain grew well within J774.1 macrophages and the mean log increase in bacteria during culture for 3 days was 2.61. Pazufloxacin, as well as other quinolones and clarithromycin, inhibited the intracellular growth of L. pneumophila at 4x MIC, while erythromycin at 4x MIC did not.
|
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In this study, the antimicrobial activity of quinolones tested against Legionella was superior to that of erythromycin. This finding supports previous reports on levofloxacin,18 ciprofloxacin19 and garenoxacin.20,21 In addition, the present study first showed that the potent activities of pazufloxacin and tosufloxacin against intracellular Legionella were superior to that of erythromycin. This study also revealed a little heterogeneity among in vitro activities of quinolones tested against Legionella. The extracellular activity (MIC) of pazufloxacin was almost the same as those of levofloxacin and ciprofloxacin, but the ratio of MIEC and MIC for pazufloxacin (2) was slightly higher than those for levofloxacin (0.5), ciprofloxacin (1) and garenoxacin (1). The relative higher MIEC of pazufloxacin may be due to less penetration of the drug into macrophages than other quinolones. One study showed that pazufloxacin distributed into rat muscle cells, but was less concentrated within the cells than ciprofloxacin and ofloxacin.22 The ratio of MIEC and MIC for tosufloxacin (0.25) was lower than those of other quinolones, suggesting this drug has excellent intracellular potency.
Present in vitro results suggested possible clinical efficacy of quinolones. In fact, clinical efficacy of levofloxacin has been confirmed,8 and that of ciprofloxacin has been reported.23,24 A case report suggested that intravenous injection of pazufloxacin mesilate was effective in Legionella infections,25 but further studies are required to verify the efficacy of the drug. Tosufloxacin and garenoxacin may be useful in Legionella infection and warrant further clinical evaluations.
In summary, our study showed that pazufloxacin and tosufloxacin were potent in vitro against Legionella spp., as were other quinolones, and more potent than macrolides and azithromycin. Present data suggested possible efficacy of these drugs in treatment of Legionella infections.
![]() |
Transparency declarations |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
Acknowledgements |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2. Meyer RD, Edelstein PH, Kirby BD et al. Legionnaires' disease: unusual clinical and laboratory features. Ann Int Med 1980; 93: 2403.[CrossRef][ISI][Medline]
3. Nash TW, Libby DM, Horwitz MA. Interaction between the Legionnaires' disease bacterium (Legionella pneumophila) and human alveolar macrophages: influence of antibody, lymphokines, and hydrocortisone. J Clin Invest 1984; 74: 77182.[ISI][Medline]
4.
Higa F, Edelstein PH. Potential virulence role of the Legionella pneumophila ptsP ortholog. Infect Immun 2001; 69: 47829.
5. Roig J, Carreres A, Domingo C. Treatment of Legionnaires' disease. Current recommendations. Drugs 1983; 46: 6379.
6. Fraser DW, Tsai TR, Orenstein W et al. Legionnaires' disease: description of an epidemic of pneumonia. N Engl J Med 1977; 297: 118997.[Abstract]
7.
Edelstein PH. Antimicrobial chemotherapy for Legionnaires' disease: time for a change. Ann Int Med 1998; 129: 32830.
8.
Yu VL, Greenberg RN, Zadeikis N et al. Levofloxacin efficacy in the treatment of community-acquired Legionellosis. Chest 2004; 125: 21359.
9. Muratani T, Inoue M, Mitsuhashi S. In vitro activity of T-3761, a new fluoroquinolone. Antimicrob Agents Chemother 1992; 36: 2293303.[Abstract]
10. Fukuoka Y, Ikeda Y, Yamashiro Y et al. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother 1993; 37: 38492.[Abstract]
11. Shimada K, Hiraga Y, Ohmichi M et al. Phase three trial of pazufloxacin mesilate. Jap J Assoc Chemother 2000; 48: 43363 (in Japanese).
12. Kohno S. Clinical assessment of tosufloxacin tosilate. J Infect Chemother 2002; 8: 1927.[Medline]
13.
Higa F, Kusano N, Tateyama M et al. Simplified quantitative assay for measuring activities of drugs against intracellular Legionella pneumophila. J Clin Microbiol 1998; 36: 13928.
14. Ezaki T, Hashimoto Y, Yamamoto H et al. Evaluation of the microplate hybridization method for rapid identification of Legionella species. Eur J Clin Microbiol Infect Dis 1990; 9: 21317.[CrossRef][ISI][Medline]
15. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003.
16. Walz A, Nichterlein T, Hof H. Excellent activity of newer quinolones on Legionella pneumophila in J774 macrophages. Zentralblatt Bakteriol 1997; 285: 4319.[ISI]
17.
Higa F, Arakaki N, Tateyama M et al. In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. J Antimicrob Chemother 2003; 52: 9204.
18. Edelstein PH, Edelstein MA, Lehr KH et al. In vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. J Antimicrob Chemother 1996; 37: 11726.[Abstract]
19. Saito A, Koga H, Shigeno H et al. The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs. J Antimicrob Chemother 1986; 18: 25160.[Abstract]
20.
Edelstein PH, Shinzato T, Edelstein MA. BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs. J Antimicrob Chemother 2001; 48: 66775.
21. Dubois J, St-Pierre C. In vitro susceptibility study of BMS-284756 against Legionella species. Diagn Microbiol Infect Dis 2001; 41: 7982.[CrossRef][ISI][Medline]
22. Araki H, Ogake N, Tsuneda R et al. Muscle distribution of antimicrobial agents after a single intravenous administration to rats. Drug Metab Phamacokinet 2002; 17: 23744.[CrossRef]
23. Zabel L, Hirschmann WD. Ciprofloxacin in the treatment of Legionnaires' disease. Pneumologie 1990; 44: 8268.[Medline]
24. Haranaga S, Tohyama M, Arakaki N et al. Legionella pneumophila pneumonia successfully treated with intravenous ciprofloxacin. Intern Med 2002; 41:10248.[ISI][Medline]
25. Higa F, Shinzato T, Tohyama M et al. Efficacy of pazufloxacin mesilate in Legionnaires' disease: a case report and in vitro study of the isolate. J Infect Chemother 2005; 11: 1648.[CrossRef][Medline]
|